On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Immunyx Pharma Ltd's own share of each project, not the project's full budget.
- Horizon Europe€253k · 1 project
Projects
1 EU-funded project, newest first. Each links to the official record.
- CANCERNAPartner
RNA PROCESSING FOR ANTI-CANCER IMMUNOTHERAPY
Horizon Europe · 2022–2025 · Project on CORDIS ↗
€253ktheir share
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
- The Hebrew University of JerusalemIsrael · 1 shared project
- Universiteit AntwerpenBelgium · 1 shared project
- Stichting Amsterdam UmcNetherlands · 1 shared project
- Fundacio Centre de Regulacio GenomicaSpain · 1 shared project
- Bar Ilan UniversityIsrael · 1 shared project
- Fundacao Gimm - Gulbenkian Institute for Molecular MedicinePortugal · 1 shared project
- Universitatsklinikum ErlangenGermany · 1 shared project
- Fundacio Institut de Recerca Contra la Leucemia Josep CarrerasSpain · 1 shared project
- Hadassah Medical OrganizationIsrael · 1 shared project
- Merck Healthcare KgaaGermany · 1 shared project
- Gsap Biomed LtdIsrael · 1 shared project
- Inter-Lab Ltd.Israel · 1 shared project
Fields it works in
Research fields recorded on its Horizon projects.
- RNA
- immunotherapy
- leukemia
- melanoma
- vaccines
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships.